Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson
Dow

Last Updated: January 27, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ZOLOFT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Zoloft

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000440 ↗ Sertraline and Naltrexone for Alcohol Dependence Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
NCT00000446 ↗ Drug Treatment for Alcoholics With Post-Traumatic Stress Disorder Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study will investigate the use of sertraline (Zoloft) to decrease alcohol consumption and crime-related post-traumatic stress disorder in those individuals with both disorders. This will be a 12-week, placebo-controlled, double-blind outpatient trial. All subjects will receive cognitive behavioral therapy in addition to a placebo or sertraline. Comprehensive evaluation will be done at study entry; treatment termination; and 6, 9, and 12 months after study entry.
NCT00000451 ↗ Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2003-01-01 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000451 ↗ Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline) Completed Yale University Phase 2 2003-01-01 This study will assess the ability of naltrexone (Revia) to reduce the risk of relapse in Alaska natives with alcohol dependence. The study will also examine whether a combination of naltrexone and sertraline (Zoloft) yields better abstinence rates than naltrexone used alone. Alaska Native individuals will be recruited into a 16 week outpatient study.
NCT00000458 ↗ Sertraline and Cognitive Therapy in Depressed Alcoholics Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study will assess whether individuals treated with sertraline (Zoloft) and cognitive behavior therapy will experience improvement with their depression and consume less alcohol than individuals treated with a placebo and cognitive behavior therapy. This is a 12-week, random assignment, placebo-controlled, double-blind study with followup assessments 1 and 3 months after treatment.
NCT00001483 ↗ Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression Completed National Institute of Mental Health (NIMH) Phase 2 1995-06-01 This study will compare the effectiveness of relatively new antidepressants which have different mechanisms of action. Buproprion (Wellbutrin) works on dopamine and the dopaminergic pathway. Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI). Venlafaxine (Effexor) works as a mixed serotonin, norepinephrine, and dopamine reuptake inhibitor. Subjects enrolled in this study will be patients diagnosed with a bipolar disorder who are presently taking medication to prevent the symptoms of the disease (prophylactic treatment), but have had breakthrough episodes of depression despite taking their medication. Patients will receive any one of the three antidepressant medications as noted above plus a placebo inactive sugar pill, in order to mask which antidepressant is being prescribed) in addition to their regular medication for bipolar disorder. All of the doses will be calculated as effective for the treatment of a unipolar major depressive disorder. The patient will continue receiving the medication for ten weeks. The effectiveness of the drug treatment will be measured by using three different scales; 1. Inventory for Depressive Symptoms - Clinicians form (IDS-C) 2. Clinical Global Impression scale(CGI-BP) 3. Life Charting Methodology (LCM) Patients who do not respond to their medication within ten weeks from the beginning of the study will be considered as non-responders and be offered the opportunity to start the study again, taking one of the two remaining medications. For example, if a patient was assigned to take Wellbutrin but it was ineffective, he/she could re-enter the study and be given either Zoloft or Effexor. Patients that do respond in the first ten weeks of the study will be eligible to continue taking the medication for one year to assess the long term effectiveness of the drug on preventing episodes of depression and to assess for any possible differential induction of mania.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zoloft

Condition Name

Condition Name for Zoloft
Intervention Trials
Depression 34
Major Depressive Disorder 16
Healthy 16
Anxiety Disorders 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zoloft
Intervention Trials
Depression 66
Depressive Disorder 55
Disease 32
Depressive Disorder, Major 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zoloft

Trials by Country

Trials by Country for Zoloft
Location Trials
United States 236
Canada 14
Australia 7
Spain 4
Brazil 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zoloft
Location Trials
New York 24
California 21
Pennsylvania 16
Texas 13
North Carolina 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zoloft

Clinical Trial Phase

Clinical Trial Phase for Zoloft
Clinical Trial Phase Trials
Phase 4 47
Phase 3 17
Phase 2/Phase 3 5
[disabled in preview] 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zoloft
Clinical Trial Phase Trials
Completed 106
Terminated 16
Recruiting 7
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zoloft

Sponsor Name

Sponsor Name for Zoloft
Sponsor Trials
National Institute of Mental Health (NIMH) 30
Pfizer 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 8
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zoloft
Sponsor Trials
Other 141
Industry 52
NIH 50
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.